Xtl Biopharmaceuticals (XTLB) Equity Income (2011)

Xtl Biopharmaceuticals (XTLB) posted quarterly Equity Income of -$115000.0 for Q4 2011.

Xtl Biopharmaceuticals (XTLB) Equity Income (2011) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Equity Income for 1 consecutive years, with -$115000.0 the latest figure, recorded in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Xtl Biopharmaceuticals 2.60 Bn 2.60 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2011 -115,000.00